UBS Group
ZBIO

UBS Group’s Zenas BioPharma ZBIO Stock Holding History

UBS Group’s Portfolio ZBIO Stock Details ZBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$4.52M Sell
178,089
-189,316
-52% -$3.76M ﹤0.01% 4271
2026
Q1 		$7.18M Buy
367,405
+297,910
+429% +$6.69M ﹤0.01% 3697
2025
Q4 		$2.52M Buy
69,495
+34,003
+96% +$1.12M ﹤0.01% 4740
2025
Q3 		$788K Buy
35,492
+11,229
+46% +$183K ﹤0.01% 5751
2025
Q2 		$235K Buy
24,263
+3,498
+17% +$34.1K ﹤0.01% 6611
2025
Q1 		$164K Sell
20,765
-110,900
-84% -$868K ﹤0.01% 6677
2024
Q4 		$1.08M Buy
131,665
+131,606
+223,061% +$2.05M ﹤0.01% 5246
2024
Q3 		$998 Buy
+59
New +$1.06K ﹤0.01% 8753

Other funds holding ZBIO

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
SOCM
SR One Capital Management Wayne, Pennsylvania $1.04B AUM 262.99% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return
ES
Enavate Sciences Menlo Park, California $345M AUM 134.64% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $42.4B AUM 181.11% 1-Year Est. Return
RPSM
Royalty Pharma Sub-Manager New York $242M AUM
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.51B AUM 546.08% 1-Year Est. Return

UBS Group's ZBIO Position: Q2 2026 in Review

UBS Group reduced its Zenas BioPharma (ZBIO) stake by 52% in Q2 2026, selling an estimated $3.76M and leaving 178,089 shares worth $4.52M. The position accounts for ﹤0.01% of the portfolio, ranked #4271.

UBS Group first reported a position in ZBIO in Q3 2024 and has held it in 8 quarters since. The position peaked at $7.18M in Q1 2026. 144 funds tracked by Wall St. Rank hold ZBIO as of Q2 2026.

  • UBS Group held 178,089 shares of Zenas BioPharma worth $4.52M as of Q2 2026.
  • UBS Group sold 189,316 Zenas BioPharma shares in Q2 2026, an estimated $3.76M.
  • Zenas BioPharma made up ﹤0.01% of UBS Group's portfolio in Q2 2026, its #4271 holding.
  • UBS Group first reported a position in Zenas BioPharma in Q3 2024 and has held it in 8 quarters since.
  • UBS Group's Zenas BioPharma position peaked at $7.18M in Q1 2026.
  • 144 funds tracked by Wall St. Rank held Zenas BioPharma as of Q2 2026.

Based on UBS Group's 13F filing for Q2 2026, filed 13 Aug 2026.